UCLA Invents Newsletter
Newsletter published by:  UCLA OIP-ISR March 2016




April 01, 2016
FirstFridays @OIP-ISR
Topic:  "Top 10 Employment Law Issues Impacting Tech Startups"
  Kayvan Iradjpanah and Eugene Ryu, Littler

June 07, 2016
Save-the-Date:  Pathways to Commercialization at UCLA

More Events


Therapeutics image

UCLA Sells Cancer Drug Royalty Rights for $1.14 Billion
UCLA has sold its royalty interest connected with a leading prostate cancer medication, Xtandi, whose development was based on discoveries by campus researchers. UCLA will hold its share of the proceeds in a broadly diversified portfolio managed by the UC office of the chief investment officer. Based on the pool’s average annual returns, UCLA anticipates it will receive approximately $60 million annually until 2027. [ more]
Prof. Eric Hoek

UCLA Ranked Among Top Universities in Tech-Transfer
UCLA is a breeding ground for innovation, and the campus has earned its place among the nation’s leaders in converting research discoveries to practical applications that benefit society. When it comes to launching startup companies based on research by faculty members, UCLA is No. 3 in the nation according to data compiled by the Association of University Technology Managers for the year ending June 30, 2014.  [ more]
Tribogenics Logo

Nikon Group Invests in UCLA Startup Tribogenics, Inc.
Nikon Americas Inc., a subsidiary company of Nikon Corporation, has made a strategic investment in Tribogenics. The investment will help speed the commercialization of Tribogenics' hand-held XRF analyzer products, using its proprietary new X-ray technology perfected by scientists at Tribogenics and the University of California, Los Angeles (UCLA). [ more]
Merganser Biotech Logo

UCLA Startup Merganser Biotech Initiates Clinical Trial
Merganser Biotech Inc., a venture-backed, clinical-stage company, announced that dosing has been initiated in the first clinical trial of M012, the company’s lead development compound. M012 is being developed as a potentially transformative therapy for rare hematological and iron overload diseases, including beta thalassemia and certain subtypes of myelodysplasia (MDS).  [ more]

Intellectual Property Announcements

New U.S. Patents Awarded

  • 9,274,181 - Magneto-optic field coupling in optical fiber bragg gratings  
    G. Carman, et al.
  • 9,273,284 - Method for generating potent dendritic cells  
    R. Modlin, et al.
  • 9,272,055 - Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles  
    M. Akhtari
  • 9,271,665 - Fabric-based pressure sensor arrays and methods for data analysis  
    M. Sarrafzadeh, et al.
  • 9,269,473 - Conductive open frameworks  
    O. Yaghi, et al.
  • 9,266,901 - Compositions and methods for treating cancer  
    M. Jung, et al.
  • 9,266,076 - Method and apparatus for real-time feedback control of electrical manipulation of droplets on chip 
    CJ Kim, et al.
  • 9,262,827 - Lung, lobe, and fissure imaging systems and methods  
    M. Brown, et al.
  • 9,261,498 - Biomarker for sensitivity to MTOR inhibitor therapy in kidney cancer  
    G. Thomas, et al.
  • 9,255,088 - Premature-termination-condons readthrough compounds  
    R. Gatti, et al.
  • 9,254,280 - Medical food for cognitive decline 
    G. Cole, et al.


New UCLA Technologies Available for Licensing



UCLA Research in the News 
UCLA INVENTS - Last month's issue
  • UCLA Grad Students Gain Insight into Technology Transfer
  • 10,000 sqft Startup Accelerator Launched at UCLA
  • UCLA Startup Receives Award for New Product Innovation
  • UCLA Inventor one of 'World’s Most Influential Scientific Minds'
  • Roundup: UCLA Startup and IP Licensing News Highlights
  • New UCLA Technologies Available for Licensing
  • UCLA Research in the News
  • UCLA Patents Awarded
UCLA TechMatch Program

Customized, automated service matches UCLA innovation with
company research and technology interests.   Subscribe to UCLA TechMatch today!

UCLA Invents Newsletter, Vol. 4, No. 7

How to Subscribe

Send editorial comments and corrections to:  
Bob Nidever, Editor   bnidever@research.ucla.edu

Contributors:  Brian Bender

UCLA Invents is published by the UCLA Office of Intellectual Property & Industry Sponsored Research
11000 Kinross Ave., Suite 200 | Los Angeles, CA 90095 | tel. 310-794-0558 | http://oip.ucla.edu

Copyright © 2016 The Regents of the University of California. All Rights Reserved.

Share this